

Victoria Medicinal Cannabis

Clinic:Regulatory Pathway Snapshot

Prepared by [yujie Cheng](#) · August 2026

Scope: Prescribing-only clinic (consultation model, no on-site dispensing)

Patient population: Adults aged 18+ only

Jurisdiction: Victoria, Australia

Prepared: August 2026

Status: Working draft,all sources require final verification against current legislation.

This document is not legal or regulatory advice.

1. Compliance Matrix

A. Federal — TGA

Federal Compliance Matrix

Prescribing-only clinic; adults 18+; Victoria. Working draft - verify against current legislation.

Requirement	Applies?	Key condition	Source
Authorised Prescriber (AP) approval	Yes - when prescribing to a class of patients	Product on Established History of Use list -> no HREC needed. Otherwise -> HREC approval or specialist-college endorsement required.	TGA AP pathway guidance
Special Access Scheme B (SAS-B)	Yes - when prescribing per individual patient	Clinical justification per patient required. Cost-based or personal-preference justifications are expressly unacceptable.	TGA SAS-B guidance
Online system registration	Source conflict exists	Treat online submission as the operational default. Do not describe online-only filing as a statutory AP requirement without resolving the hierarchy: SAS material says submissions "must be lodged" online; AP guidance calls online filing the "preferred method"; an approved-forms instrument preserves a paper AP form available on request.	TGA SAS online system; AP online system; Therapeutic Goods (AP Scheme - Application Form) Approval (No. 2) 2024
Prescription-medicine advertising compliance	Yes - Day 1 requirement	Review the business name, website, paid search, social media, booking funnel and service descriptions. June 2026 guidance directly addresses services that prescribe or supply medicinal cannabis; TGA initiated Federal Court proceedings in Aug 2026 over alleged unlawful advertising.	TGA prescription-medicine advertising guidance (Jun 2026)

Source: Primary government pages cited in the report, checked August 2026. This image is not legal or regulatory advice.
Prepared by YUIJE CHENG

B. State — Victoria

State Compliance Matrix - Victoria

Prescribing-only clinic; adults 18+. Working draft - verify against current legislation.

Requirement	Applies?	Key condition	Source
Clinic operating licence	No - prescribing-only clinic does not require separate health-service-establishment registration	Registration applies to private hospitals, day procedure centres and mobile health services only.	Victorian Department of Health
Schedule 8 permit	Conditional	Required only for drug-dependent patients; not required for non-drug-dependent patients.	Victorian Department of Health - medicinal cannabis for health professionals
SafeScript check	Yes - every prescription	Prescriber must check SafeScript before each Schedule 8 medicinal-cannabis prescription, regardless of patient status.	Victorian Department of Health - SafeScript
Stock possession licence	Only if the clinic holds or supplies product on-site	If not exempt under a Commonwealth ODC licence, a separate Victorian licence is required under the Drugs, Poisons and Controlled Substances Act 1981.	Victorian Department of Health - licences and permits

Source: Victorian Department of Health materials cited in the report, checked August 2026. This image is not legal or regulatory advice.
Prepared by YUIJE CHENG

C. AHPRA / Medical Board

AHPRA and Medical Board Compliance Matrix

Clinical-governance obligations are the report's main operating-model risk.

Requirement	Applies?	Key condition	Source
Practitioner registration	General or Specialist registration required	Non-practising registration holders cannot prescribe.	AHPRA - types of medical registration
Specialist accreditation	Not required (adults 18+)	"Medical practitioners do not need to gain accreditation, nor be specialists in a particular field."	Victorian Department of Health FAQ
Medicinal-cannabis prescribing governance	Yes - critical	Full patient assessment; identified therapeutic need; not first-line treatment; management plan; continuity of care; records; exit strategy. "Patient demand is no indicator of clinical need." AHPRA may investigate abnormally high prescribing volumes without a complaint.	Medical Board - medicinal-cannabis prescribing guidance (2025)
Asynchronous prescribing constraint	Risk flag	Real-time video or telephone consultation is acceptable. Prescribing through questionnaires, email, text or asynchronous chat without direct consultation is described as "not good practice" and is not supported by the Board.	Medical Board - telehealth consultations
Conflict of interest	Risk flag	Single-product or single-class businesses and vertically integrated prescribing-supply arrangements are flagged by regulators as risk factors.	Medical Board guidance; TGA 2025 consultation

Source: AHPRA, Medical Board and Victorian Department of Health materials cited in the report. Not legal or regulatory advice.
Prepared by YUJIE CHENG

2. Pathway Sequence

Step 1 — Practitioner Setup

- Confirm AHPRA General or Specialist registration (active)
- Register on TGA SAS & AP Online System
- Estimated time: 1–3 days

Step 2 — Advertising & Branding Compliance Review

- Review business name, website, all marketing materials against TGA prescription medicine advertising guidance
- This step is non-negotiable before public launch
- Estimated time: varies (legal review recommended)

Step 3 — Choose Access Pathway

- AP route (class of patients)
 - Check if product is on Established History of Use list
 - Yes → submit AP application (no HREC needed)
 - No → obtain HREC approval or college endorsement first (timeline: variable — weeks to months)
- SAS-B route (individual patients)
 - Submit per-patient application with clinical justification

Step 4 — TGA Approval

- Medicinal cannabis applications: 2–5 business days (after submission of all required information)
- AP approval valid: up to 5 years; reports every 6 months
- SAS-B: validity as specified in approval letter; commonly granted for up to 24 months (delegate discretion)
- Category-based approvals (since Nov 2021):
 - Within same approved category → product substitution may not require new TGA application
 - Outside approved category → new application required

Step 5 — Victoria State Compliance

- Register with SafeScript
- Assess patient drug-dependency status
 - Non-dependent → no state permit needed
 - Dependent → apply for Schedule 8 permit via SafeScript
- Confirm clinic model does NOT require health service establishment registration

Step 6 — Clinical Governance Setup

- Establish full patient assessment protocol
- Document therapeutic need and treatment alternatives considered
- Build management plan and exit strategy templates
- Set up continuity-of-care and referral pathways
- Declare and manage any conflicts of interest (especially prescribing-supply arrangements)
- Establish medical records and monitoring protocols

3. Risk Flags

Risk Flags

The report locates material risk in the clinical and commercial operating model, not clinic establishment.

Risk	Detail	Potential impact
Advertising non-compliance	TGA is actively enforcing prescription-medicine advertising rules against medicinal-cannabis businesses. Business names, digital marketing and booking funnels are in scope.	Federal Court proceedings possible; may require a business-name change, website redesign and marketing overhaul before launch.
Asynchronous prescribing	Real-time telehealth is viable. Questionnaire-led or other async-only models without a live consultation are not supported by the Medical Board.	Virtual-first works if built on real-time consultations; an async-only model is a regulatory liability.
Clinical-governance deficiency	AHPRA may investigate high-volume prescribers without a complaint. Short consultations, absent assessments and demand-driven prescribing are explicit red flags.	Practitioner registration at risk; reputational damage to the clinic.
Conflict of interest	Vertically integrated prescribing + supply models and single-product clinics are specifically flagged by TGA and AHPRA.	Business-model design must address conflict management from Day 1.
Product-category boundary	Category-based approvals permit substitution only within the approved cannabinoid category, dosage form and indication; substitution outside those boundaries requires a new TGA application.	Supply disruption may create an operational-continuity risk if a substitute crosses categories; manageable within category.
Drug-dependent patient misclassification	Classifying a drug-dependent patient as non-dependent bypasses the Schedule 8 permit requirement.	Prescriber liability and enforcement action.

Source: TGA, AHPRA, Medical Board and Victorian Department of Health materials cited in the report. Not legal or regulatory advice.
Prepared by YUJIE CHENG

4. Regulatory Horizon Scan (2025–2026)

Regulatory Horizon Scan - 2025 to 2026

No replacement prescribing framework had commenced as of August 2026; advertising enforcement was already active.

Date	Event	Status	Potential impact
Aug-Oct 2025	TGA consultation: safety and regulatory-framework review	Feedback updated 21 Apr 2026; 786 submissions. Stakeholders broadly agreed the access framework was "not fit-for-purpose" or proportionate to potential safety and quality risks.	Signals reform direction; no new rules yet enacted.
28 Jul 2026	Medicinal Cannabis Expert Working Group - Meeting 8 (published 25 Aug 2026)	TGA outlined a staged reform program, including consideration of updates to TGO 93. Members discussed risks for palliative-care patients and vertically integrated telehealth models.	Any substantial TGO 93 amendments remain subject to consultation.
May 2026	TGA guidance: compounded medicines (including medicinal cannabis)	Published	Additional restrictions for compounded cannabis products.
Jun 2026	TGA guidance: prescription-medicine advertising	Published	Active enforcement underway; directly affects marketing of medicinal-cannabis prescribing services.
Jun-Jul 2026	Consultation: remaking Narcotic Drugs Regulation 2016	Closed 22 Jun-19 Jul 2026	May affect cultivation and manufacturing licences; downstream impact on product supply.

Source: TGA consultations, guidance and working-group materials cited in the report. Working draft; not legal or regulatory advice.
Prepared by YUJIE CHENG

Assessment: No replacement prescribing framework has commenced, but reform has progressed beyond consultation stage. TGA is developing a staged reform program. Any clinic established now should build compliance review into its operating model at minimum 6-month intervals. The advertising enforcement is not future, it is current.

5. Key Insight

The formal licensing barrier for a prescribing-only Victorian clinic is relatively limited:

- No clinic-specific licence required
- No specialist accreditation required (adults 18+)
- No state permit required for non-drug-dependent patients
- TGA medicinal cannabis approval timeline: 2–5 business days (faster than standard 15-day AP pathway)
- Category-based approvals reduce product-substitution friction

The material regulatory risk sits in the clinical and commercial operating model, not in clinic establishment.

The question in 2026 is not "Can I legally establish this clinic?" but "Can I operate a high-volume, digitally acquired, virtual-first medicinal cannabis prescribing business without the business model itself distorting clinical decision-making or creating unlawful advertising?"

This is where regulators are focused: consultation quality, conflict of interest, advertising compliance, prescribing volumes, and single-purpose business models. A clinic that solves the licensing pathway but ignores operating model governance has solved the wrong problem.

Sources:

TGA ([tga.gov.au](https://www.tga.gov.au)), Victorian Department of Health ([health.vic.gov.au](https://www.health.vic.gov.au))

AHPRA ([ahpra.gov.au](https://www.ahpra.gov.au))

Medical Board of Australia

Office of Drug Control ([odc.gov.au](https://www.odc.gov.au))

Legislation references: Drugs, Poisons and Controlled Substances Act 1981 (Vic), Narcotic Drugs Act 1967 (Cth), Therapeutic Goods (AP Scheme, Application Form) Approval (No. 2) 2024.

All dates and sources verified against primary government pages as of August 2026.

Prepared by [yujie Cheng](#) · August 2026